Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.67 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342130 | 0.89 | EPHX2 (0.54) | EPHX2EPHX1TRPM8SIGMAR1CYP2C9 | |
| SCHEMBL29964837 | 0.83 | TRPM8 (0.71) | EPHX2EPHX1TRPM8SIGMAR1DRD2 | |
| SCHEMBL30724364 | 0.82 | TRPM8 (0.66) | EPHX2EPHX1TRPM8SIGMAR1DRD2 | |
| SCHEMBL12695008 | 0.80 | EPHX2 (1.00) | EPHX2EPHX1TRPM8SIGMAR1CYP2C9 | |
| SCHEMBL1912694 | 0.78 | TRPM8 (0.73) | EPHX2EPHX1TRPM8SIGMAR1DRD2 | |
| SCHEMBL2346305 | 0.78 | EPHX2 (0.52) | EPHX2EPHX1TRPM8DRD2HTR2A | |
| SCHEMBL20616667 | 0.76 | TRPM8 (0.59) | EPHX2EPHX1TRPM8SIGMAR1DRD2 | |
| SCHEMBL12449442 | 0.76 | EPHX2 (0.48) | EPHX2EPHX1TRPM8DRD2HTR2A | |
| SCHEMBL1912695 | 0.75 | TRPM8 (0.68) | EPHX2EPHX1TRPM8SIGMAR1DRD2 | |
| SCHEMBL12695216 | 0.75 | EPHX2 (0.73) | EPHX2EPHX1TRPM8SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310389-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310389-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8524713-B2 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524713-B2 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524713-B2 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2257553-B1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON INC (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2257553-B1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON INC (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2257553-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100298332-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298332-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298332-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009097309-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097309-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298332-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | EPHX2 1028/4885EPHX1 902/4885TRPM8 251/4885 |
| US-20130310389-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | EPHX2 1736/4885EPHX1 792/4885TRPM8 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.